November 18, 2026
Health news, explained with evidence
LIVE

FDA Approves First New Advanced Head and Neck Cancer Treatment in a Decade

🧠 AI Analysis 2 min read 👁 5

The U.S. Food and Drug Administration has granted accelerated approval to Rybrevant Faspro for adults with advanced head and neck squamous cell carcinoma.

FDA Approves First New Advanced Head and Neck Cancer Treatment in a Decade🧠AI Analysis

Photo: Medical Xpress

Key points

  • FDA grants accelerated approval to Rybrevant Faspro for advanced HNSCC.
  • First new drug approval for this patient group in a decade.
  • Clinical trial showed a 42% overall response rate among 102 patients.

The U.S. Food and Drug Administration has cleared Janssen Biotech's Rybrevant Faspro, combining amivantamab and hyaluronidase-lpuj, to treat adults diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This authorization applies specifically to individuals whose condition has advanced despite previous treatments involving platinum-based chemotherapy and immunotherapy. Notably, this decision marks the first new drug approval for this patient group in ten years, though the treatment is not intended for human papillomavirus-associated oropharyngeal squamous cell carcinoma.

This regulatory decision is based on clinical data from a trial involving 102 patients with recurrent or metastatic HNSCC. The findings indicate that Rybrevant Faspro achieved an overall response rate of 42%, contrasted with a 20% rate seen with standard therapies. Furthermore, among the participants who responded to the medication, 56% maintained that response for a duration of six months or longer. Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, noted that the authorization offers a significant development for an illness where therapeutic choices have traditionally been restricted.

Because the authorization relies on an early-stage trial of 102 patients and was granted via the accelerated pathway, further clinical verification may be required to confirm long-term clinical benefits. Readers should consult qualified healthcare professionals regarding personal medical choices and treatment plans.

What to know

  • Drug Name: Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
  • Indication: Recurrent or metastatic HNSCC progressing after chemotherapy and immunotherapy
  • Clinical Results: 42% overall response rate compared to 20% for current standard therapies

Source Medical Xpress — medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.